Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of neflamapimod in dementia with Lewy bodies
2023-504373-20-00Phase 2Completed
- Sponsor
- CervoMed
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) comparing Neflamapimod with Placebo (2 arms). Primary endpoint: Change from baseline to Week 16 in CDR-SB. Started Jul 2023; status: completed.
02
Drugs
neflamapimod
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on 2023-504373-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504373-20-00.